Blood tests using vesicles to track liver disease outcomes

Trial details

Who runs it

Assistance Publique - Hôpitaux de Paris

Trial code

NCT07185360

Record updated

22 September 2025

Original description

Worldwide, cirrhosis is responsible for 2 million deaths per year. Hepatocellular carcinoma (HCC) accounts for 800,000 of these deaths and is the 3rd leading cause of cancer related death. Cirrhosis affects mainly a working age population, hence its heavy economic burden.While patients with compensated cirrhosis do not have symptoms and have a 10-year life expectancy, decompensation of cirrhosis heralds a dramatic decrease in life expectancy to 2 years. Biomarkers allowing reliable estimation of the risk for decompensation of cirrhosis would allow community-based care, possibly by nurse practitioners, of patients at low risk, while patients had high risk could be managed in secondary and tertiary care centers and included in clinical trials. Because HCC is usually asymptomatic at early stages, when it is still curable, it can easily be missed. Biomarkers allowing stratification of the risk of HCC would allow reinforced surveillance (using magnetic resonance imaging) of high-risk patients, and their inclusion in chemoprevention clinical trials.Read full original descriptionShow less

Liver Diseases: Extracellular Vesicles as Biomarkers

Worldwide, cirrhosis is responsible for 2 million deaths per year. Hepatocellular carcinoma (HCC) accounts for 800,000 of these deaths and is the 3rd leading cause of cancer related death. Cirrhosis affects mainly a working age population, hence its heavy economic burden.While patients with compensated cirrhosis do not have symptoms and have a 10-year life expectancy, decompensation of cirrhosis heralds a dramatic decrease in life expectancy to 2 years. Biomarkers allowing reliable estimation of the risk for decompensation of cirrhosis would allow community-based care, possibly by nurse practitioners, of patients at low risk, while patients had high risk could be managed in secondary and tertiary care centers and included in clinical trials. Because HCC is usually asymptomatic at early stages, when it is still curable, it can easily be missed. Biomarkers allowing stratification of the risk of HCC would allow reinforced surveillance (using magnetic resonance imaging) of high-risk patients, and their inclusion in chemoprevention clinical trials.

LIVER-TRACK aims at reliably predicting the outcome of patients with compensated cirrhosis through the development of a Tests for Decompensation and a Test for HCC. This will be achieved through leveraging circulating extracellular vesicles (EVs), an untapped source of biomarkers in liver diseases, as prognostic indicators, and combining them with existing blood biomarkers and single-nucleotide polymorphisms (SNPs). LIVER-TRACK also aims at delivering technologies for EV measurement that are useable in medical practice.

Inclusion: Patient aged 18 or over; Type 2 diabetic (ADA/WHO criteria recalled in section 20.5); Hepatic fibrosis stage F3/F4 on liver biopsy or hepatic elasticity > 10 kPa; Major; Child-Pugh A, B or C cirrhosis, diagnosed on the basis of histological evidence or liver elasticity > 15 kPa or a combination of biological and radiological signs.

Exclusion: Presence of one of the following diseases in the 15 days prior to inclusion: acute renal failure, bacterial infection (proven or suspected on clinico-biological criteria), digestive bleeding,; alcoholic hepatitis in the month prior to inclusion; Previous porto-systemic shunt, liver transplantation, primary sclerosing cholangitis, primary biliary cholangitis, Budd-Chiari syndrome; Known liver disease; Active cancer; Viral or bacterial infection within 2 weeks of inclusion (respiratory, dermatological, urinary, digestive, etc.); Vulnerable person: a person deprived of liberty by a judicial or administrative decision, or under psychiatric care, and a person admitted to a health or social institution for purposes other than research; Illness linked to other etiologies:; Alcoholic liver disease; Current hepatitis B virus infection; Current hepatitis C virus infection; Autoimmune hepatitis according to according to AASLD and EASL recommended criteria; Transferrin saturation >50%; Alpha antitrypsin ZZ or SZ type deficiency; Wilson's disease; Liver transplant patients; Ultrasound obstruction of blood vessels or bile ducts (on routine ultrasound). If nothing is mentioned on the report, it is considered that there is no obstruction of the blood vessels or bile ducts); Current participation or less than 3 months' participation in a therapeutic interventional trial; Patients with liver disease :; Transfusion in the month preceding inclusion; Current participation or less than 3 months' participation in a therapeutic interventional trial; Absence of signed informed consent; Not affiliated to a social security scheme; Pregnant women; Person under guardianship or trusteeship; Diabetic patients with F3/F4 fibrosis recruited and followed prospectively; Protected adult; Not affiliated to or not benefiting from a social security scheme; Pregnant or breast-feeding women; Absence of signed informed consent; Active or past hepatocellular carcinoma; Active extrahepatic neoplasia,; Current participation or less than 3 months' participation in a therapeutic interventional trial; Absence of signed informed consent; Non affiliation to a social security scheme; Pregnant or breast-feeding; Person under guardianship or trusteeship.

Volunteers without liver disease; Inclusion criteria: Major.

ClinicalTrials.gov NCT07185360